science glp 1 ICYMI, named the development of glucagon-like peptide-1 (#GLP1) agonists and last year's discovery that these drugs can blunt obesity-associated health problems as the 2023 #BreakthroughOfTheYear. Learn more: https://t.co/RwIK5Kkg3E #BOTY The Breakthrough of the Year
Description
The next scientific breakthrough in the GLP-1 field came about after Habener brokered a collaboration between Mojsov and Gordon Weir, a physician and renowned diabetologist at the Joslin Diabetes Center in Boston, Massachusetts, that (like MGH) is associated with Harvard Medical School
* 24.9 or less No 25.0 26.9 Case by case ** 27.0 29.9 Likely ** 30.0 or above Likely Find your BMI on the chart below to see if you're within the indicated range for Zepbound treatment
Available from: Nguyen TMD
[DOI] [PMC free article] [PubMed] [Google Scholar] 77.He Y, Huang Y, Xu H, Yang X, Liu N, Xu Y, et al
GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions
On rest days, an afternoon protein shake helps meet daily targets
